A Rapid Method to Quantitatively Screen Bispecific Antibodies Using Protein A and Octet^® His1K Biosensors

Application Note

Recent advances in biotechnology have driven the development of bispecific antibodies. But for those working in bioprocessing or cell line screening, there still remains a number of development challenges. Many traditional technologies for characterizing antibodies are limited in their ability to provide quantitative functional assessment of two interactions to one bispecific molecule, and commonly used assay platforms like ELISA and SPR are time-intensive.

Scientists at Celgene Corporation developed a screening process incorporating the Octet^® platform. Now they can identify pools and clones with higher concentrations of bispecific antibodies. High-throughput was achieved from the multiple simultaneous measures possible on the system and rapid assays times, such as binding optimization in only 10 minutes.